Every material Form 8-K Cronos Group Inc. has filed with the SEC since September 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cronos Group reported third-quarter 2026 results on November 5, 2026. Net revenue rose 75% year over year to $63.5 million and Adjusted EBITDA rose to $17.1 million, but net income fell 37% to $17.8 million, mainly due to lower other income, higher operating expenses and an income tax provision compared with a benefit a year earlier. For shareholders, sales and operating profit grew while bottom-line net income declined.
Net revenue was $63.5 million in Q3 2026, up from $36.3 million in Q3 2025, a 75% increase.
Gross profit was $32.3 million, up 76%, and Adjusted EBITDA was $17.1 million, up from $5.7 million.
Net income was $17.8 million, down from $28.3 million in Q3 2025, a 37% decline.
In Q3 2026 the company repurchased 3.2 million shares for $9.4 million; the CanAdelaar acquisition closed on October 15, 2026.
Cronos completed its acquisition of CanAdelaar B.V., a Dutch cannabis grower, on October 15, 2026, for a base price of €57.5 million plus contingent cash consideration tied to 2026 and 2027 Normalized EBITDA. The final Minister decision in a Bibob background review was still outstanding at closing, and an Addendum gives Cronos indemnities from seller Ring, subject to caps. The filing also shows CanAdelaar's Adjusted EBITDA declining from €24.2 million in the twelve months ended September 30, 2025 to €20.1 million annualized for the first half of 2026.
Base purchase price of €57.5 million, subject to closing and post-closing adjustments, plus contingent consideration equal to 50% of CanAdelaar's 2026 and 2027 Normalized EBITDA
Final Minister decision on the Bibob review was outstanding at closing; Ring indemnities cap liability at €22.5 million for the first two matters
€12.5 million proposed DCMR odor penalty treated as indebtedness and deducted from the estimated closing price
CanAdelaar Adjusted EBITDA was €20.1 million annualized for the six months ended June 30, 2026, versus €24.2 million for the twelve months ended September 30, 2025
Cronos Group amended its share purchase agreement to acquire CanAdelaar B.V., a Dutch licensed cannabis grower, pushing the long stop date from September 9 to October 15, 2026. The filing does not describe any change to price or other terms, and the rest of the agreement remains in effect.
Second SPA Amendment dated September 8, 2026, extends the Long Stop Date from September 9, 2026 to October 15, 2026.
CanAdelaar is one of ten licensed cannabis growers in the Dutch Controlled Cannabis Supply Chain Experiment.
Except for the deadline change, the original agreement dated December 9, 2025 remains in full force.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cronos Group Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →